Table 2.
Adjusted odds ratios for patient and tumor characteristics by breast cancer subtypes, SEER-18, excluding Alaska, 2010*
| Characteristics | HR + /HER2 − † | Triple-negative | HR + /HER2 + | HR − /HER2 + | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 31 500 | n = 5140 | n = 4270 | n = 1849 | ||||||||||
| % Case patients | % Case patients | Odds ratio‡ (95% CI) | % Case patients | Odds ratio‡ (95% CI) | % Case patients | Odds ratio‡ (95% CI) | |||||||
| Race/ethnicity | |||||||||||||
| NH white (referent) | 75 | 62 | 1.0 | 68 | 1.0 | 62 | 1.0 | ||||||
| NH black | 8 | 19 | 2.0 (1.8 to 2.2) | 11 | 1.2 (1.0 to 1.3) | 13 | 1.4 (1.2 to 1.6) | ||||||
| NH API | 8 | 6 | 0.8 (0.7 to 0.9) | 10 | 1.2 (1.1 to 1.4) | 12 | 1.8 (1.5 to 2.1) | ||||||
| Hispanic | 9 | 12 | 1.3 (1.2 to 1.5) | 11 | 1.1 (1.0 to 1.2) | 12 | 1.4 (1.2 to 1.6) | ||||||
| Age at diagnosis, y | |||||||||||||
| <50 | 19 | 26 | 1.0 (0.9 to1.1) | 30 | 1.3 (1.2 to 1.4) | 26 | 0.9 (0.8 to 1.0) | ||||||
| 50–64 (referent) | 37 | 41 | 1.0 | 39 | 1.0 | 44 | 1.0 | ||||||
| 65–74 | 23 | 19 | 0.9 (0.8 to 0.9) | 18 | 0.8 (0.7 to 0.9) | 17 | 0.7 (0.6 to 0.8) | ||||||
| ≥75 | 20 | 14 | 0.8 (0.7 to 0.9) | 13 | 0.7 (0.6 to 0.8) | 14 | 0.7 (0.6 to 0.8) | ||||||
| AJCC 7th stage at diagnosis | |||||||||||||
| I (referent) | 51 | 38 | 1.0 | 43 | 1.0 | 36 | 1.0 | ||||||
| II | 31 | 42 | 1.1 (1.0 to 1.2) | 36 | 1.1 (1.0 to 1.1) | 36 | 1.1 (1.0 to 1.2) | ||||||
| III | 10 | 16 | 1.0 (0.9 to 1.1) | 16 | 1.2 (1.1 to 1.4) | 20 | 1.6 (1.3 to 1.8) | ||||||
| IV | 3 | 5 | 1.0 (0.8 to 1.2) | 5 | 1.4 (1.2 to 1.7) | 8 | 2.1 (1.7 to 2.6) | ||||||
| Bloom–Richardson grade | |||||||||||||
| Low (referent) | 34 | 7 | 1.0 | 12 | 1.0 | 7 | 1.0 | ||||||
| Medium | 48 | 18 | 1.9 (1.7 to 2.1) | 42 | 2.3 (2.1 to 2.5) | 26 | 2.6 (2.1 to 3.2) | ||||||
| High | 17 | 75 | 20.0 (17.8 to 22.5) | 46 | 6.4 (5.8 to 7.1) | 67 | 16.8 (13.9 to 20.5) | ||||||
* AJCC = American Joint Committee on Cancer; API = Asian Pacific Islander; HER2, human epidermal growth factor receptor; HR = hormone receptor; NH = non-Hispanic; SEER = Surveillance, Epidemiology, and End Results.
† The HR+/HER2− subtype (ie, the most common of all subtypes) serves as a reference group.
‡ All odds ratios are calculated after controlling for race/ethnicities, age, stage, tumor grade, and SEER registries. Analysis is based on complete cases. Polytomous logistic regression. All statistical tests were two-sided.